Gili Hart

Gili Hart's work experience includes serving as the Chief Executive Officer at SpliSense, a clinical stage company focused on RNA-based treatments for pulmonary diseases. They have also served as a Board Member at Enlivex Therapeutics and Quicklizard. Gili Hart was a member of Cohort #2 at 8400 The Health Network. They have been a Board Member at CollPlant since 2016 and will continue in that role until 2023. Gili Hart has also held the position of Chief Executive Officer at Mitoconix Bio. Ltd, where they led the development of the company's pipeline and capabilities in mitochondrial function. Prior to that, they served as the General Manager at OPKO Biologics and as the VP of Preclinical and Clinical Pharmacology at OPKP Biologics (previously known as Prolor Biotech LTD). They also worked as the Senior Director of Preclinical and Clinical Pharmacology at Prolor Biotech LTD.

Gili Hart's education history begins in 1996 when they graduated from the Technion Institute of Technology in Haifa, Israel with a Bachelor of Science (B.Sc) degree in Biotechnology Engineering. From 2000 to 2002, they pursued a Master of Science (MSc) degree in Immunology at the Weizmann Institute of Science. Following that, they obtained their PhD in Immunology from the same institute, completing their studies from 2002 to 2005. From 2005 to 2006, Gili Hart served as a Research Fellow in the Immunology Department at both the Weizmann Institute and Yale School of Medicine.